MBX Biosciences, Inc. Common Stock (MBX) 10-Year Financial Performance & Capital Metrics

MBX • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutMBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Show more

Revenue $0
EBITDA -$68M -93.3%
Net Income -$62M -90.2%
EPS (Diluted) -1.85 -81.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -66.95%
ROIC -96.87%
Debt/Equity 0.00
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 96 (top 4%)
✓Trading near 52-week high

✗Weaknesses

✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-45.88%

EPS CAGR

10Y-

5Y-

3Y-

TTM-43.11%

ROCE

10Y Avg-52.9%

5Y Avg-52.9%

3Y Avg-52.9%

Latest-40.38%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.73B	5.64	58.02	43.5%	9.32%		1.89%
CORTCorcept Therapeutics Incorporated	3.82B	36.35	29.55	39.94%	14.19%	16.65%	5.12%	0.01
GUTSFractyl Health, Inc. Common Stock	308.28M	2.01	-1.24	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	436.08M	1.20	-1.90	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	229.96M	2.48	-2.53			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	164.38M	1.93	-2.88	-100%		-282.97%		4.17
ALTAltimmune, Inc.	418.41M	4.01	-2.99	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	741.84M	20.69	-3.12		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0
Revenue Growth %	-	-	-
Cost of Goods Sold+	0	0	0
COGS % of Revenue	-	-	-
Gross Profit+	0	0	0
Gross Margin %	-	-	-
Gross Profit Growth %	-	-	-
Operating Expenses+	25.16M	35.31M	68.19M
OpEx % of Revenue	-	-	-
Selling, General & Admin	3.76M	6.78M	10.78M
SG&A % of Revenue	-	-	-
Research & Development	21.4M	28.53M	57.41M
R&D % of Revenue	-	-	-
Other Operating Expenses	0	0	0
Operating Income+	-25.16M	-35.31M	-68.19M
Operating Margin %	-	-	-
Operating Income Growth %	-	-0.4%	-0.93%
EBITDA+	-25.11M	-35.15M	-67.95M
EBITDA Margin %	-	-	-
EBITDA Growth %	-	-0.4%	-0.93%
D&A (Non-Cash Add-back)	56K	157K	244K
EBIT	-25.76M	-35.31M	-68.19M
Net Interest Income+	-2K	2.75M	6.27M
Interest Income	372K	2.75M	6.27M
Interest Expense	374K	0	0
Other Income/Expense	-974K	2.75M	6.27M
Pretax Income+	-26.14M	-32.56M	-61.92M
Pretax Margin %	-	-	-
Income Tax+	0	0	0
Effective Tax Rate %	1%	1%	1%
Net Income+	-26.14M	-32.56M	-61.92M
Net Margin %	-	-	-
Net Income Growth %	-	-0.25%	-0.9%
Net Income (Continuing)	-26.14M	-32.56M	-61.92M
Discontinued Operations	0	0	0
Minority Interest	0	0	0
EPS (Diluted)+	-0.82	-1.02	-1.85
EPS Growth %	-	-0.24%	-0.81%
EPS (Basic)	-0.82	-1.02	-1.85
Diluted Shares Outstanding	31.85M	31.85M	33.39M
Basic Shares Outstanding	31.85M	31.85M	33.39M
Dividend Payout Ratio	-	-	-

Balance Sheet

	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	44.21M	83.47M	267.29M
Cash & Short-Term Investments	42.46M	80.68M	262.15M
Cash Only	24.21M	30.52M	49.35M
Short-Term Investments	18.25M	50.15M	212.8M
Accounts Receivable	142K	208K	682K
Days Sales Outstanding	-	-	-
Inventory	0	0	0
Days Inventory Outstanding	-	-	-
Other Current Assets	84K	133K	803K
Total Non-Current Assets+	884K	715K	1.25M
Property, Plant & Equipment	842K	665K	1.2M
Fixed Asset Turnover	-	-	-
Goodwill	0	0	0
Intangible Assets	0	0	0
Long-Term Investments	0	0	0
Other Non-Current Assets	42K	50K	50K
Total Assets+	45.09M	84.18M	268.54M
Asset Turnover	-	-	-
Asset Growth %	-	0.87%	2.19%
Total Current Liabilities+	3.43M	3.93M	11.05M
Accounts Payable	976K	1.39M	5.33M
Days Payables Outstanding	-	-	-
Short-Term Debt	0	0	0
Deferred Revenue (Current)	0	0	0
Other Current Liabilities	1.13M	1.36M	2.32M
Current Ratio	12.89x	21.26x	24.19x
Quick Ratio	12.89x	21.26x	24.19x
Cash Conversion Cycle	-	-	-
Total Non-Current Liabilities+	84.27M	152.72M	42K
Long-Term Debt	0	0	0
Capital Lease Obligations	324K	171K	0
Deferred Tax Liabilities	0	0	0
Other Non-Current Liabilities	83.94M	152.55M	42K
Total Liabilities	87.7M	156.65M	11.09M
Total Debt+	461K	324K	171K
Net Debt	-23.75M	-30.2M	-49.18M
Debt / Equity	-	-	0.00x
Debt / EBITDA	-	-	-
Net Debt / EBITDA	-	-	-
Interest Coverage	-67.28x	-	-
Total Equity+	-42.6M	-72.47M	257.44M
Equity Growth %	-	-0.7%	4.55%
Book Value per Share	-1.34	-2.28	7.71
Total Shareholders' Equity	-42.6M	-72.47M	257.44M
Common Stock	1K	1K	5K
Retained Earnings	-43.02M	-75.58M	-137.5M
Treasury Stock	0	0	0
Accumulated OCI	3K	60K	55K
Minority Interest	0	0	0

Cash Flow

	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-23.12M	-31.98M	-54.68M
Operating CF Margin %	-	-	-
Operating CF Growth %	-	-0.38%	-0.71%
Net Income	-26.14M	-32.56M	-61.92M
Depreciation & Amortization	56K	157K	244K
Stock-Based Compensation	306K	2.04M	5.22M
Deferred Taxes	0	0	0
Other Non-Cash Items	1.36M	-880K	-2.82M
Working Capital Changes	1.29M	-735K	4.6M
Change in Receivables	0	0	0
Change in Inventory	0	0	0
Change in Payables	671K	412K	3.93M
Cash from Investing+	-11.41M	-30.93M	-160.59M
Capital Expenditures	-441K	-129K	-874K
CapEx % of Revenue	-	-	-
Acquisitions	-	-	-
Investments	-	-	-
Other Investing	0	0	0
Cash from Financing+	46.06M	69.22M	234.1M
Debt Issued (Net)	-	-	-
Equity Issued (Net)	-	-	-
Dividends Paid	0	0	0
Share Repurchases	-	-	-
Other Financing	-428K	709K	-3.94M
Net Change in Cash	-	-	-
Free Cash Flow+	-23.56M	-32.11M	-55.55M
FCF Margin %	-	-	-
FCF Growth %	-	-0.36%	-0.73%
FCF per Share	-0.74	-1.01	-1.66
FCF Conversion (FCF/Net Income)	0.88x	0.98x	0.88x
Interest Paid	0	0	0
Taxes Paid	0	0	0

Key Ratios

Metric	2022	2023	2024
Return on Equity (ROE)	-	-	-66.95%
Return on Invested Capital (ROIC)	-	-	-96.87%
Debt / Equity	-	-	0.00x
Interest Coverage	-67.28x	-	-
FCF Conversion	0.88x	0.98x	0.88x

Frequently Asked Questions

Growth & Financials

MBX Biosciences, Inc. Common Stock (MBX) grew revenue by 0.0% over the past year. Growth has been modest.

MBX Biosciences, Inc. Common Stock (MBX) reported a net loss of $80.5M for fiscal year 2024.

Dividend & Returns

MBX Biosciences, Inc. Common Stock (MBX) has a return on equity (ROE) of -67.0%. Negative ROE indicates the company is unprofitable.

MBX Biosciences, Inc. Common Stock (MBX) had negative free cash flow of $78.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener